The Cholesterol Transport Inhibitor U18666A Interferes with Pseudorabies Virus Infection

Many viruses require the maintenance of lysosomal cholesterol homeostasis for a successful infection; however, the role of lysosomal cholesterol homeostasis in the alphaherpesvirus life cycle is not clear. Here we show that the lysosomal cholesterol transport inhibitor U18666A interferes with the replication of pseudorabies virus (PRV), a member of the alphaherpesvirus subfamily. The treatment with U18666A caused a significant reduction in the production of infectious virus particles. The U18666A treatment was shown to suppress the release of PRV particles. Pretreating PRV virions with U18666A did not affect virus production, whereas pretreating target cells with U18666A led to a substantial reduction in virus yield. Our previous study showed that two cyclodextrin derivatives, 2-hydroxypropyl-beta-cyclodextrin (HP beta CD) and 2-hydroxypropyl-gamma-cyclodextrin (HP gamma CD), can rescue the cholesterol accumulation defect in primary fibroblasts derived from a Niemann-Pick disease type C (NPC) patient. Here, we demonstrate that treatment with HP beta CD or HP gamma CD not only rescues the U18666A-induced cholesterol accumulation but also rescues the U18666A-induced inhibition of PRV production. Collectively, our data suggest that U18666A interferes with PRV infection via altering cellular functions that are critical for the viral life cycle and may include lysosomal cholesterol homeostasis.

Automated summary

Lysosomal cholesterol homeostasis plays an important role in the alphaherpesvirus life cycle. Inhibitor U18666A interferes with the replication of pseudorabies virus (PRV). Treatment with HP beta CD or HP gamma CD rescues U18666A-induced cholesterol accumulation and inhibits PRV production.